Melanoma Clinical Trial

A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)

Summary

This study will compare the efficacy and safety of belzutifan + lenvatinib versus cabozantinib in participants with advanced renal cell carcinoma (RCC) with clear cell component after prior therapy.

The primary hypothesis is that belzutifan + lenvatinib is superior to cabozantinib in terms of progression-free survival or overall survival.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Unresectable, locally advanced or metastatic clear cell renal cell carcinoma (RCC).
Disease progression on or after an anti-programmed cell death-1/ligand 1 (PD-1/L1) therapy as either first or second-line treatment for locally advanced/metastatic RCC or as adjuvant treatment or neoadjuvant/adjuvant with progression on or within 6 months of last dose.
Measurable disease per RECIST 1.1 criteria as assessed by local study investigator.
Karnofsky performance status (KPS) score of at least 70% assessed within 10 days before randomization.
Received no more than 2 prior systemic regimens including: one anti-PD-1/L1 containing adjuvant or neoadjuvant/adjuvant regimens with progression on or within 6 months from the last dose of that regimen OR one or 2 regimens for locoregional/advanced disease
Received only 1 prior antiPD-1/L1 therapy for adjuvant, neoadjuvant/adjuvant or locally advanced/metastatic RCC.
A male participant is eligible to participate if he is abstinent from heterosexual intercourse or agrees to use contraception during the intervention period and for at least 7 days after the last dose of belzutifan or lenvatinib in the belzutifan+lenvatinib arm, whichever occurs last, and 23 days after the last dose of cabozantinib.
A female participant is eligible to participate if they are not pregnant, not breastfeeding, and at least 1 of the following conditions applies: Not a woman of childbearing potential (WOCBP) or a WOCBP who agrees to follow the contraceptive guidance during the intervention period and for at least 30 days after the last dose of study intervention in the belzutifan+ lenvatinib arm, or 120 days after the last dose of study intervention in the cabozantinib arm.
Adequately controlled blood pressure.
Adequate organ function.

Exclusion Criteria:

A pulse oximeter reading <92% at rest, requires intermittent supplemental oxygen, or requires chronic supplemental oxygen.
Known additional malignancy that is progressing or has required active treatment within the past 3 years except for basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (eg, breast carcinoma, cervical cancer in situ) that have undergone potentially curative therapy.
Known central nervous system (CNS) metastases and/or carcinomatous meningitis.
Clinically significant cardiac disease within 6 months of first dose of study intervention.
Prolongation of QTc interval to >480 ms.
Symptomatic pleural effusion (e.g.,cough, dyspnea, pleuritic chest pain) that is not clinically stable.
Pre-existing ≥Grade 3 gastrointestinal or nongastrointestinal fistula.
Moderate to severe hepatic impairment.
History of significant bleeding within 3 months before randomization.
History of solid organ transplantation.
Known psychiatric or substance abuse disorder that would interfere with cooperation with the requirements of the study.
Unable to swallow orally administered medication or has a gastrointestinal disorder affecting absorption (e.g., gastrectomy, partial bowel obstruction, malabsorption).
Known hypersensitivity or allergy to the active pharmaceutical ingredients or any component of the study intervention formulations.
Received colony-stimulating factors [eg, granulocyte colony-stimulating factor (G-CSF), granulocyte macrophage colony-stimulating factor (GMCSF) or recombinant erythropoietin (EPO)] within 28 days before randomization.
Prior treatment with belzutifan or another hypoxia-inducible factor (HIF)-2α inhibitor.
Prior treatment with lenvatinib.
Prior treatment with cabozantinib.
Currently participating in a study of an investigational agent or using an investigational device.
Active infection requiring systemic therapy.
History of human immunodeficiency virus (HIV) infection.
History of hepatitis B or known active hepatitis C infection.

Study is for people with:

Melanoma

Phase:

Phase 3

Estimated Enrollment:

708

Study ID:

NCT04586231

Recruitment Status:

Recruiting

Sponsor:

Merck Sharp & Dohme LLC

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 164 Locations for this study

See Locations Near You

Ironwood Cancer & Research Centers ( Site 0077)
Chandler Arizona, 85224, United States More Info
Study Coordinator
Contact
480-398-7674
Cedars Sinai Medical Center ( Site 0027)
Los Angeles California, 90048, United States More Info
Study Coordinator
Contact
310-423-3713
UCLA Hematology/Oncology - Santa Monica ( Site 0048)
Los Angeles California, 90404, United States More Info
Study Coordinator
Contact
310-633-8400
St. Joseph Hospital-The Center for Cancer Prevention and Treatment ( Site 0095)
Orange California, 92868, United States More Info
Study Coordinator
Contact
714-734-6220
UC Irvine Health ( Site 0029)
Orange California, 92868, United States More Info
Study Coordinator
Contact
714-509-2450
Providence Saint John's Health Center ( Site 0083)
Santa Monica California, 90404, United States More Info
Study Coordinator
Contact
310-315-6125
Georgetown University Medical Center ( Site 0006)
Washington District of Columbia, 20007, United States More Info
Study Coordinator
Contact
202-687-1116
AdventHealth Orlando-AdventHealth Medical Group Hematology & Oncology at Orlando ( Site 0003)
Orlando Florida, 32804, United States More Info
Study Coordinator
Contact
407-303-2024
Orlando Health, Inc. ( Site 0035)
Orlando Florida, 32806, United States More Info
Study Coordinator
Contact
321-841-3812
University Cancer & Blood Center, LLC ( Site 0057)
Athens Georgia, 30607, United States
Emory University Hospital ( Site 0012)
Atlanta Georgia, 30322, United States
Rush University Medical Center ( Site 0040)
Chicago Illinois, 60612, United States More Info
Study Coordinator
Contact
312-942-3732
Illinois Cancer Care, PC ( Site 0008)
Peoria Illinois, 61615, United States More Info
Study Coordinator
Contact
309-243-3000
Parkview Cancer Institute ( Site 0088)
Fort Wayne Indiana, 46845, United States More Info
Study Coordinator
Contact
260-266-7745
Norton Cancer Institute - St. Matthews ( Site 0065)
Louisville Kentucky, 40207, United States More Info
Study Coordinator
Contact
502-899-3366
Tulane University School of Medicine ( Site 0098)
New Orleans Louisiana, 70112, United States More Info
Study Coordinator
Contact
504-988-6300
Lahey Hospital & Medical Center ( Site 0090)
Burlington Massachusetts, 01805, United States More Info
Study Coordinator
Contact
781-744-2998
Cancer & Hematology Centers of Western Michigan ( Site 0018)
Grand Rapids Michigan, 49503, United States More Info
Study Coordinator
Contact
269-993-6056
HealthPartners Cancer Research Center-HealthPartners Frauenshuh Cancer Center ( Site 0005)
Saint Louis Park Minnesota, 55426, United States
University of Mississippi Medical Ctr ( Site 0037)
Jackson Mississippi, 39213, United States More Info
Study Coordinator
Contact
601-815-4540
Cancer Partners of Nebraska ( Site 0086)
Lincoln Nebraska, 68510, United States More Info
Study Coordinator
Contact
402-420-7000
Rutgers Cancer Institute of New Jersey ( Site 0078)
New Brunswick New Jersey, 08903, United States More Info
Study Coordinator
Contact
732-235-2465
Northwell Health- Monter Cancer Center ( Site 0013)
Lake Success New York, 11042, United States More Info
Study Coordinator
Contact
516-734-8916
Memorial Sloan Kettering Cancer Center ( Site 0055)
New York New York, 10065, United States More Info
Study Coordinator
Contact
646-888-4722
Levine Cancer Institute ( Site 0004)
Charlotte North Carolina, 28204, United States More Info
Study Coordinator
Contact
980-442-9715
Duke Cancer Institute ( Site 0096)
Durham North Carolina, 27710, United States More Info
Study Coordinator
Contact
919-613-1909
Lehigh Valley Hospital- Cedar Crest-Oncology Clinical Trials ( Site 0056)
Allentown Pennsylvania, 18103, United States More Info
Study Coordinator
Contact
610-402-1184
University of Texas, Southwestern Medical Center ( Site 0015)
Dallas Texas, 75390, United States More Info
Study Coordinator
Contact
214-645-8787
University of Vermont Medical Center ( Site 0001)
Burlington Vermont, 05401, United States More Info
Study Coordinator
Contact
802-656-4909
Blue Ridge Cancer Care - Roanoke ( Site 0043)
Roanoke Virginia, 24014, United States More Info
Study Coordinator
Contact
504-381-5291
Seattle Cancer Care Alliance-Renal/Melanoma/MCC ( Site 0093)
Seattle Washington, 98109, United States More Info
Study Coordinator
Contact
206-606-6326
Confluence Health | Wenatchee Valley Hospital & Clinics ( Site 0061)
Wenatchee Washington, 98801, United States More Info
Study Coordinator
Contact
509-664-4868
Centro de Urología (CDU) ( Site 0803)
Caba Buenos Aires, C1120, Argentina More Info
Study Coordinator
Contact
541149642424
Hospital Británico de Buenos Aires-Oncology ( Site 0801)
Ciudad autónoma de Buenos Aires Buenos Aires, C1280, Argentina More Info
Study Coordinator
Contact
+541143096897
Instituto Alexander Fleming ( Site 0800)
Ciudad Autónoma de Buenos Aires Buenos Aires, C1426, Argentina More Info
Study Coordinator
Contact
+541132218900
Sanatorio Parque ( Site 0806)
Rosario Santa Fe, 2000, Argentina More Info
Study Coordinator
Contact
+543414200222
Sanatorio Británico-Clinical Oncology Department ( Site 0802)
Rosario Santa Fe, S2000, Argentina More Info
Study Coordinator
Contact
+543414205500
Asociación de Beneficencia Hospital Sirio Libanés ( Site 0804)
Buenos Aires , C1419, Argentina More Info
Study Coordinator
Contact
541145740870
GenesisCare North Shore ( Site 4011)
St Leonards New South Wales, 2065, Australia More Info
Study Coordinator
Contact
+61280374100
Lyell McEwin Hospital ( Site 4004)
Elizabeth Vale South Australia, 5112, Australia More Info
Study Coordinator
Contact
+6188282 0833
Peninsula Health Frankston Hospital ( Site 4001)
Frankston Victoria, 3199, Australia More Info
Study Coordinator
Contact
+61397847175
Peter MacCallum Cancer Centre-Parkville Cancer Clinical Trials Unit (PCCTU) ( Site 4010)
Melbourne Victoria, 3000, Australia More Info
Study Coordinator
Contact
+61385595000
Ordensklinikum Linz GmbH Elisabethinen-Urologie ( Site 1001)
Linz Oberosterreich, 4020, Austria More Info
Study Coordinator
Contact
+4373276774724
Medizinische Universitätsklinik Graz ( Site 1051)
Graz Steiermark, 8036, Austria More Info
Study Coordinator
Contact
4331638513028
Klinik Ottakring-1.Medizinische Abteilung - Zentrum für Onkologie und Hämatologie ( Site 1031)
Vienna Wien, 1160, Austria More Info
Study Coordinator
Contact
+43 149 150 2145
Krankenhaus der Barmherzigen Brüder Wien ( Site 1041)
Wien , 1020, Austria More Info
Study Coordinator
Contact
431211212100
Medizinische Universität Wien ( Site 1021)
Wien , 1090, Austria More Info
Study Coordinator
Contact
+43 1 40400 44290
Institut Jules Bordet ( Site 1103)
Anderlecht Bruxelles-Capitale, Region De, 1070, Belgium More Info
Study Coordinator
Contact
+3225417320
Grand Hopital de Charleroi ( Site 1104)
Charleroi Hainaut, 6000, Belgium More Info
Study Coordinator
Contact
+3271104750
UZ Gent ( Site 1100)
Gent Oost-Vlaanderen, 9000, Belgium More Info
Study Coordinator
Contact
+3293322811
UZ Leuven ( Site 1101)
Leuven Vlaams-Brabant, 3000, Belgium More Info
Study Coordinator
Contact
003216346900
CHU de Liege ( Site 1102)
Liege , 4000, Belgium More Info
Study Coordinator
Contact
003243667801
Liga Norte Riograndense Contra o Cancer ( Site 0313)
Natal Rio Grande Do Norte, 59151, Brazil More Info
Study Coordinator
Contact
+558440095595
Centro Gaucho Integrado de Oncologia ( Site 0304)
Porto Alegre Rio Grande Do Sul, 90110, Brazil More Info
Study Coordinator
Contact
55 51 3307.2943
Hospital Paulistano - Amil Clinical Research ( Site 0308)
Sao Paulo , 01321, Brazil More Info
Study Coordinator
Contact
+551194476385
Real e Benemerita Associacao Portuguesa de Beneficencia ( Site 0311)
Sao Paulo , 01323, Brazil More Info
Study Coordinator
Contact
+5511 3505 6675
Tom Baker Cancer Centre ( Site 0109)
Calgary Alberta, T4N 4, Canada More Info
Study Coordinator
Contact
403 5213166
Cross Cancer Institute ( Site 0111)
Edmonton Alberta, T6G 1, Canada More Info
Study Coordinator
Contact
780-432-8762
BC Cancer Vancouver-Clinical Trials Unit ( Site 0110)
Vancouver British Columbia, V5Z 4, Canada More Info
Study Coordinator
Contact
6048776000
The Moncton Hospital ( Site 0101)
Moncton New Brunswick, E1C 6, Canada More Info
Study Coordinator
Contact
506-857-5669
Hamilton Health Sciences-Juravinski Cancer Centre ( Site 0114)
Hamilton Ontario, L8V 5, Canada More Info
Study Coordinator
Contact
905-387-9495
Kingston Health Sciences Centre ( Site 0105)
Kingston Ontario, K7L 2, Canada More Info
Study Coordinator
Contact
613-549-6666x7313
The Ottawa Hospital - General Campus-The Ottawa Hospital Cancer Centre ( Site 0116)
Ottawa Ontario, K1H 8, Canada More Info
Study Coordinator
Contact
6137377700
Sunnybrook Health Sciences - Odette Cancer Centre ( Site 0113)
Toronto Ontario, M4N 3, Canada More Info
Study Coordinator
Contact
416-480-6100 ex.5847
CISSS de la Monteregie-Centre ( Site 0103)
Greenfield Park Quebec, J4V 2, Canada More Info
Study Coordinator
Contact
450-466-5000x3226
Centre intégré de cancérologie du CHU de Québec Université Laval, Hôpital de l'Enfant-Jésus ( Site 0
Quebec City Quebec, G1J 1, Canada More Info
Study Coordinator
Contact
418-525-4444 ex.67712
CIUSSS de l Estrie - CHUS - Centre Hosp. Univ. Sherbrooke ( Site 0102)
Sherbrooke Quebec, J1H 5, Canada More Info
Study Coordinator
Contact
8193461110x12811
James Lind Centro de Investigación del Cáncer ( Site 0402)
Temuco Araucania, 48008, Chile More Info
Study Coordinator
Contact
+56452982404
Bradfordhill-Clinical Area ( Site 0400)
Santiago Region M. De Santiago, 84203, Chile More Info
Study Coordinator
Contact
+56229490970
Clínica Vida Fundación - Sede Poblado ( Site 0505)
Medellin Antioquia, 05003, Colombia More Info
Study Coordinator
Contact
573126867004
Sociedad De Oncologia Y Hematologia Del Cesar-Oncology ( Site 0508)
Valledupar Cesar, 20000, Colombia More Info
Study Coordinator
Contact
573128385292
Instituto Nacional de Cancerología-Clinical Oncology ( Site 0500)
Bogotá Cundinamarca, 11151, Colombia More Info
Study Coordinator
Contact
573108658288
Fundación Cardiovascular de Colombia ( Site 0501)
Piedecuesta Santander, 68101, Colombia More Info
Study Coordinator
Contact
+5776399658
Masarykuv onkologicky ustav-Klinika komplexni onkologicke pece ( Site 2203)
Brno Brno-mesto, 656 5, Czechia More Info
Study Coordinator
Contact
+420543132216
Nemocnice České Budějovice-Onkologicke oddeleni ( Site 2204)
České Budějovice Jihocesky Kraj, 370 0, Czechia More Info
Study Coordinator
Contact
+420387872075
Fakultni Thomayerova nemocnice-Onkologicka klinika 1. LF UK ( Site 2200)
Prague Praha 4, 140 5, Czechia More Info
Study Coordinator
Contact
+420261083530
Fakultni nemocnice Hradec Kralove-Klinika onkologie a radioterapie ( Site 2201)
Hradec Kralove , 500 0, Czechia More Info
Study Coordinator
Contact
+420495832176
Tampereen yliopistollinen sairaala ( Site 1801)
Tampere Pirkanmaa, 33520, Finland More Info
Study Coordinator
Contact
+358331163082
HYKS ( Site 1800)
Helsinki Uusimaa, 00290, Finland More Info
Study Coordinator
Contact
+358504279697
TYKS ( Site 1802)
Turku Varsinais-Suomi, 20520, Finland More Info
Study Coordinator
Contact
+35823130729
Institut Jean Godinot ( Site 1216)
Reims Ain, 51726, France More Info
Study Coordinator
Contact
+33326504485
Centre Antoine Lacassagne ( Site 1217)
Nice Alpes-Maritimes, 06189, France More Info
Study Coordinator
Contact
+33492031538
Institut de cancérologie Strasbourg Europe (ICANS) ( Site 1218)
Strasbourg Alsace, 67033, France More Info
Study Coordinator
Contact
0368767208
CHU de Bordeaux- Hopital Saint Andre ( Site 1209)
Bordeaux Gironde, 33075, France More Info
Study Coordinator
Contact
+33556795679
Institut Claudius Regaud ( Site 1215)
Toulouse Haute-Garonne, 31059, France More Info
Study Coordinator
Contact
+33531155829
Clinique Francois Chenieux ( Site 1210)
Limoges Haute-Vienne, 87039, France More Info
Study Coordinator
Contact
33555454800
Institut de Cancerologie de l Ouest Centre Rene Gauducheau ( Site 1201)
Saint Herblain Loire-Atlantique, 44805, France More Info
Study Coordinator
Contact
+33 (0)240679900
Institut de Cancerologie de l Ouest Site Paul Papin ( Site 1200)
Angers Maine-et-Loire, 49055, France More Info
Study Coordinator
Contact
+33(0)240679900
Hopital Tenon ( Site 1213)
Paris , 75020, France More Info
Study Coordinator
Contact
+33156017110
Klinik fuer Urologie ( Site 1303)
Freiburg Baden-Wurttemberg, 79106, Germany More Info
Study Coordinator
Contact
+49 761 270 90030
NCT-Department of Medical Oncology ( Site 1320)
Heidelberg Baden-Wurttemberg, 69120, Germany More Info
Study Coordinator
Contact
+496221 56 6857
Klinikum Nuernberg Nord ( Site 1300)
Nuremberg Bayern, 90419, Germany More Info
Study Coordinator
Contact
+49 911 398 3085
Universitaetsklinikum Frankfurt ( Site 1301)
Frankfurt am Main Hessen, 60590, Germany More Info
Study Coordinator
Contact
+49 69 630 186463
Universitaetsklinikum Aachen AOER ( Site 1317)
Aachen Nordrhein-Westfalen, 52074, Germany More Info
Study Coordinator
Contact
+49 241 80 36596
Krankenhaus Martha Maria Halle-Doelau ( Site 1314)
Halle Sachsen-Anhalt, 06120, Germany More Info
Study Coordinator
Contact
+493455591449
Helios Klinikum Erfurt GmbH ( Site 1315)
Erfurt Thuringen, 99089, Germany More Info
Study Coordinator
Contact
00493617812201
Charite Universitaetsmedizin Berlin ( Site 1321)
Berlin , 10117, Germany More Info
Study Coordinator
Contact
0049 30 450 615092
HELIOS Klinikum Berlin-Buch ( Site 1311)
Berlin , 13125, Germany More Info
Study Coordinator
Contact
0049 30 9401 14888
UNIVERSITY HOSPITAL OF PATRAS-DIVISION OF ONCOLOGY ( Site 3302)
Patras Achaia, 26504, Greece More Info
Study Coordinator
Contact
+302610999791
Alexandra General Hospital of Athens-ONCOLOGY DEPT. ( Site 3304)
Athens Attiki, 115 2, Greece More Info
Study Coordinator
Contact
+302132162513
Athens Medical Center ( Site 3303)
Athens Attiki, 151 2, Greece More Info
Study Coordinator
Contact
+302106157392
Mater Misericordiae University Hospital ( Site 3201)
Dublin 7 Dublin, D07 A, Ireland More Info
Study Coordinator
Contact
+35318032000
Tallaght University Hospital ( Site 3200)
Dublin , D24NR, Ireland More Info
Study Coordinator
Contact
+35314144299
Mater Private Hospital - Dublin ( Site 3202)
Dublin , , Ireland More Info
Study Coordinator
Contact
+35318032000
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori ( Site 1407)
Meldola Forli-Cesena, 47014, Italy More Info
Study Coordinator
Contact
+390543739100
Istituto Clinico Humanitas Research Hospital ( Site 1406)
Rozzano Milano, 20089, Italy More Info
Study Coordinator
Contact
+390282244080
Ospedale San Luigi Gonzaga ( Site 1405)
Orbassano Torino, 10043, Italy More Info
Study Coordinator
Contact
390119026993
Medical Oncology Ospedale San Donato ( Site 1404)
Arezzo , 52100, Italy More Info
Study Coordinator
Contact
+390575255436
Azienda Ospedaliera Policlinico di Bari ( Site 1402)
Bari , 70124, Italy More Info
Study Coordinator
Contact
+390805594167
IRCCS Ospedale San Raffaele ( Site 1409)
Milano , 20132, Italy More Info
Study Coordinator
Contact
+390226437626
Fondazione IRCCS Istituto Nazionale dei Tumori di Milano ( Site 1400)
Milano , 20133, Italy More Info
Study Coordinator
Contact
+390223904450
Istituti Clinici Scientifici Maugeri Spa ( Site 1403)
Pavia , 27100, Italy More Info
Study Coordinator
Contact
+390382592679
Fondazione Policlinico Universitario Agostino Gemelli-Medical Oncology ( Site 1410)
Roma , 00168, Italy More Info
Study Coordinator
Contact
+390630154953
Azienda Ospedaliera S. Maria di Terni ( Site 1401)
Terni , 05100, Italy More Info
Study Coordinator
Contact
390744205410
Ospedale Maggiore Borgo Trento ( Site 1408)
Verona , 37126, Italy More Info
Study Coordinator
Contact
+390458122768
Fujita Health University ( Site 5003)
Toyoake Aichi, 470-1, Japan More Info
Study Coordinator
Contact
+81-562-93-2111
National Cancer Center Hospital East ( Site 5000)
Kashiwa Chiba, 27785, Japan More Info
Study Coordinator
Contact
+81-4-7133-1111
Sapporo Medical University Hospital ( Site 5008)
Sapporo Hokkaido, 060-8, Japan More Info
Study Coordinator
Contact
+81-11-611-2111
Yokohama City University Hospital ( Site 5007)
Yokohama Kanagawa, 236-0, Japan More Info
Study Coordinator
Contact
+81-45-787-2800
Nara Medical University Hospital ( Site 5002)
Kashihara Nara, 634-8, Japan More Info
Study Coordinator
Contact
+81-744-22-3051
Kindai University Hospital- Osakasayama Campus-Urology ( Site 5010)
Osakasayama Osaka, 589-8, Japan More Info
Study Coordinator
Contact
+81-72-366-0221
Osaka University Hospital ( Site 5012)
Suita Osaka, 565-0, Japan More Info
Study Coordinator
Contact
+81-6-6879-5111
Hamamatsu University School of Medicine University Hospital ( Site 5004)
Hamamatsu Shizuoka, 431-3, Japan More Info
Study Coordinator
Contact
+81-53-435-2111
Tokyo Medical And Dental University Medical Hospital ( Site 5009)
Bunkyo-ku Tokyo, 113-8, Japan More Info
Study Coordinator
Contact
+81-3-3813-6111
Toranomon Hospital ( Site 5001)
Minato-ku Tokyo, 10584, Japan More Info
Study Coordinator
Contact
+81-3-3588-1111
Kyushu University Hospital ( Site 5005)
Fukuoka , 812-8, Japan More Info
Study Coordinator
Contact
+81-92-641-1151
Niigata University Medical & Dental Hospital ( Site 5013)
Niigata , 951-8, Japan More Info
Study Coordinator
Contact
+81-25-223-6161
Nippon Medical School Hospital ( Site 5006)
Tokyo , 113-8, Japan More Info
Study Coordinator
Contact
+81-3-3822-2131
Keio university hospital ( Site 5011)
Tokyo , 160-8, Japan More Info
Study Coordinator
Contact
+81-3-3353-1211
Chonnam National University Hwasun Hospital-Oncology ( Site 4203)
Hwasun Jeonranamdo, 58128, Korea, Republic of More Info
Study Coordinator
Contact
+82613797700
Asan Medical Center ( Site 4200)
Seoul , 05505, Korea, Republic of More Info
Study Coordinator
Contact
+82230106095
Samsung Medical Center ( Site 4201)
Seoul , 06351, Korea, Republic of More Info
Study Coordinator
Contact
+82221487394
Medisch Centrum Leeuwarden ( Site 1905)
Leeuwarden Fryslan, 8934 , Netherlands More Info
Study Coordinator
Contact
+31582866666
Zuyderland Medical Centre-Trialbureau Interne Geneeskunde ( Site 1904)
Sittard-Geleen Limburg, 6162 , Netherlands More Info
Study Coordinator
Contact
+31582866010
Amphia Hospital Location Molengracht ( Site 1912)
Breda Noord-Brabant, 4818 , Netherlands More Info
Study Coordinator
Contact
+31765955000
Antoni van Leeuwenhoek Ziekenhuis ( Site 1901)
Amsterdam Noord-Holland, 1066 , Netherlands More Info
Study Coordinator
Contact
+31205122569
Erasmus MC ( Site 1913)
Rotterdam Zuid-Holland, 3015G, Netherlands More Info
Study Coordinator
Contact
+31107041754
Franciscus Gasthuis & Vlietland, Locatie Vlietland ( Site 1909)
Schiedam Zuid-Holland, 3118 , Netherlands More Info
Study Coordinator
Contact
+31108939393
Universitair Medisch Centrum Utrecht ( Site 1910)
Utrecht , 3584 , Netherlands More Info
Study Coordinator
Contact
+31887555555
Centrum Onkologii im. Prof. Franciszka Lukaszczyka ( Site 2402)
Bydgoszcz Kujawsko-pomorskie, 85-79, Poland More Info
Study Coordinator
Contact
48501446778
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - O-Klinika Onkologii Klinicznej ( Site 240
Krakow Malopolskie, 31-11, Poland More Info
Study Coordinator
Contact
+48126348268
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie ( Site 2400)
Warszawa Mazowieckie, 02-78, Poland More Info
Study Coordinator
Contact
+48225462331
Szpital Kliniczny Przemienienia Panskiego Uniwersytetu Medycznego ( Site 2401)
Poznan Wielkopolskie, 60-56, Poland More Info
Study Coordinator
Contact
48618549038
Ivanovo Regional Oncology Dispensary ( Site 2616)
Ivanovo Ivanovskaya Oblast, 15304, Russian Federation
MEDSI Clinical Hospital on Pyatnitsky Highway-Departmentof Antitumor Drug therapy ( Site 2618)
Krasnogorsk Moskovskaya Oblast, 14344, Russian Federation
Hadassah Medical-Oncology department ( Site 2609)
Moscow Moskovskaya Oblast, 12120, Russian Federation
FSBI United Hospital with Polyclinic ( Site 2613)
Moscow Moskva, 11928, Russian Federation
SHI of Moscow City Oncology Clinical Hospital - 62 ( Site 2614)
Moscow Moskva, 12513, Russian Federation
Volgograd Regional Uronephrological Center ( Site 2615)
Volzhsky Volgogradskaya Oblast, 40412, Russian Federation
Yaroslavl Regional Cancer Hospital-Oncology ( Site 2619)
Yaroslavl Yaroslavskaya Oblast, 15005, Russian Federation
Complejo Hospitalario Universitario A Coruna ( Site 1502)
A Coruna La Coruna, 15006, Spain
Hospital Universitario 12 de Octubre-Medical Oncology ( Site 1508)
Madrid Madrid, Comunidad De, 28041, Spain More Info
Study Coordinator
Contact
+34913908339
Hospital Universitari Vall d'Hebron-Departamento de Oncologia- VHIO ( Site 1507)
Barcelona , 08035, Spain More Info
Study Coordinator
Contact
+34934894350
Hospital Clinic i Provincial ( Site 1500)
Barcelona , 08036, Spain More Info
Study Coordinator
Contact
+34932275400
Hospital Santa Creu i Sant Pau ( Site 1501)
Barcelona , 08041, Spain More Info
Study Coordinator
Contact
+34935537453
Hospital General Universitario Gregorio Maranon ( Site 1505)
Madrid , 28009, Spain More Info
Study Coordinator
Contact
+34914269393
Hospital Clinico San Carlos ( Site 1504)
Madrid , 28040, Spain More Info
Study Coordinator
Contact
+34913303000 x3133
Hospital Virgen del Rocio ( Site 1503)
Sevilla , 41013, Spain More Info
Study Coordinator
Contact
+34955013068
Hopitaux Universitaires de Geneve HUG ( Site 1602)
Geneva Geneve, 1211, Switzerland More Info
Study Coordinator
Contact
+41795532353
Kantonsspital Graubuenden ( Site 1600)
Chur Grisons, 7000, Switzerland More Info
Study Coordinator
Contact
+41812566646
Istituto Oncologica della Svizzera Italiana (IOSI) ( Site 1604)
Bellinzona Ticino, 6500, Switzerland More Info
Study Coordinator
Contact
+41918118463
Universitaetsspital Zuerich ( Site 1601)
Zuerich Zurich, 8091, Switzerland More Info
Study Coordinator
Contact
+492118108776
Aberdeen Royal Infirmary-Department of Oncology ( Site 3105)
Aberdeen Aberdeen City, AB25 , United Kingdom More Info
Study Coordinator
Contact
+441224553624
Royal United Hospital Bath England ( Site 3108)
Bath Bath And North East Somerset, BA1 3, United Kingdom More Info
Study Coordinator
Contact
+441225428331
Nottingham University Hospitals NHS Trust. City Hospital Campus ( Site 3106)
Nottingham England, NG5 1, United Kingdom More Info
Study Coordinator
Contact
+441159691169
Imperial Healthcare NHS Trust Charing Cross Hospital ( Site 3107)
London London, City Of, W6 8R, United Kingdom More Info
Study Coordinator
Contact
00442033115160
Mount Vernon Cancer Centre ( Site 3101)
Northwood London, City Of, HA6 2, United Kingdom More Info
Study Coordinator
Contact
+442038262020
Musgrove Park Hospital ( Site 3103)
Taunton Somerset, TA1 5, United Kingdom More Info
Study Coordinator
Contact
+4401823342001
Singleton Hospital ( Site 3111)
Swansea Wales, SA2 8, United Kingdom More Info
Study Coordinator
Contact
+441792285521

How clear is this clinincal trial information?

Study is for people with:

Melanoma

Phase:

Phase 3

Estimated Enrollment:

708

Study ID:

NCT04586231

Recruitment Status:

Recruiting

Sponsor:


Merck Sharp & Dohme LLC

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.